ANIP
Ani Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$81.84
+0.34 (+0.42%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 714.59M | 504.44M | 655.83M | 587.23M | 677.58M |
| Net Income | -21,543,308 | -13,686,980 | 91.62M | 76.98M | 94.84M |
| EPS | — | — | — | — | — |
| Profit Margin | -3.0% | -2.9% | 14.0% | 13.1% | 14.0% |
| Rev Growth | +41.7% | +41.7% | -1.8% | +23.0% | +20.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 545.22M | 545.22M | 350.73M | 377.30M | 386.46M |
| Total Equity | 374.21M | 374.21M | 750.78M | 736.99M | 759.49M |
| D/E Ratio | 1.46 | 1.46 | 0.47 | 0.51 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 66.08M | 44.32M | 150.31M | 125.34M | 137.44M |
| Free Cash Flow | — | — | 73.49M | 59.62M | 74.72M |